Cited by 39Sleep and related disordersSubstance Abuse Treatment and OutcomesObstructive Sleep Apnea Research

Rebound insomnia after hypnotic withdrawal in insomniac outpatients

Hajak, G., Clarenbach, P., Fischer, W., Rodenbeck, A., Bandelow, B., Broocks, A., Rüther, E.·1998·European Archives of Psychiatry and Clinical Neuroscience

Abstract

The effect of abrupt medication withdrawal (no-pill discontinuation) was investigated in 1507 insomniacs using the patients' self-ratings on visual analogue scales. Drug discontinuation followed a 28-day treatment period with either 7.5 mg zopiclone, 0.25 mg triazolam, 1.0 mg flunitrazepam, or placebo in a randomized, double-blind, parallel group, multicenter study in private practice. Deterioration below individual pretreatment values (no-pill baseline) in at least one of three subjective parameters of sleep quality (sleep latency, total sleep time, nocturnal awakenings) and three parameters of daytime well-being (morning freshness, daytime tiredness, anxiety) were defined as rebound. The number of patients with rebound (rebound rate) was analyzed for every day of a 2-week posttreatment period. The overall rebound rate was higher in the placebo group (p < or = 0.001) than in each group treated with active drugs. Rebound rates affecting sleep quality were higher for placebo than for zopiclone (p < or = 0.001) and for flunitrazepam (p < or = 0.05). Rebound rates were smaller for zopiclone (p < or = 0.001) and flunitrazepam (p < or = 0.01) than for triazolam. Rebound in at least one item per day appeared in 21.5% (sleep quality) and 25.5% (daytime well-being) of the patients. Rebound decreased with increasing numbers of items of sleep quality or daytime well-being. Patients who did not respond to treatment showed higher rebound rates than those who were treatment responders (p < or = 0.001). Concerning treatment nonresponders, highest rebound was seen in the placebo group, whereas rebound was lowest in placebo responders. These results show that pill discontinuation itself may worsen sleep and daytime well-being in the sense of a rebound phenomenon. Furthermore, the number of patients with rebound remained at a high and varying level during the whole posttreatment period. This result indicates that a deterioration of sleep after drug withdrawal is not apparent during a few days but may last for longer periods in some patients and is modified by marked night-to-night variations.

Integrity signals

Registry

Crossref · 10.1007/s004060050032

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The citation lists haven’t been fetched yet

References 36 · Cited by 39

Authors
Hajak, G., Clarenbach, P., Fischer, W., Rodenbeck, A., Bandelow, B., Broocks, A., & Rüther, E.
Affiliations
University of Göttingen (DE)
Venue
European Archives of Psychiatry and Clinical Neuroscience
Published
1998-07-28
Volume
248
Issue
3
Pages
148-156
ISSN
  • 0003-9373 (ISSN-L)
  • 0940-1334
  • 1433-8491
OpenAlex
W2009316739
Cited by
39
References
36
Citations by year
2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2012: 3
FWCI
2.40
Type
journal article
Language
en
Open access
closed
Locations
  • European Archives of Psychiatry and Clinical Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Physiology › Obstructive Sleep Apnea Research
Keywords
rebound insomnia, hypnotic withdrawal, insomnia, zopiclone, triazolam, flunitrazepam, benzodiazepines, sleep quality, treatment non-responders, outpatients
MeSH terms
Adolescent, Adult, Aged, Analysis of Variance, Double-Blind Method, Drug Administration Schedule, Female, Flunitrazepam, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Piperazines, Placebos, Recurrence, Sleep, Anti-Anxiety Agents, Triazolam, Treatment Outcome, Azabicyclo Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review